Ryan Allway May 3rd, 2021 Psychedelics San Diego, California–(Newsfile Corp. – May 3, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) (“Tryp”) a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today a master service agreement with Fluence to provide design and training for the... Read more
Ryan Allway April 30th, 2021 Psychedelics, Top News Mental illness is the leading cause of disability in developed countries. In fact, half of Americans will experience mental illness in their lifetime and $350 billion is spent each year on treating depression in the U.S. and Europe alone. Psychedelics have... Read more
Ryan Allway April 29th, 2021 Psychedelics VANCOUVER, British Columbia, April 29, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”), a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce that it has... Read more
Lobe Sciences Announces Filing of PCT Application
April 29, 2021
Ryan Allway April 29th, 2021 Psychedelics Vancouver, British Columbia–(Newsfile Corp. – April 29, 2021) – Lobe Sciences Ltd. (“Lobe“) (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce the filing of a key Patent Cooperation Treaty (“PCT”) application entitled Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury,... Read more
Lobe Sciences Enters into LOI with Core One Labs to Form a Joint Venture for the Clinical Development of Biosynthetic Psilocybin
April 29, 2021
Ryan Allway April 29th, 2021 Psychedelics Vancouver, British Columbia–(Newsfile Corp. – April 28, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) is pleased to announce it has entered into a non-binding letter of intent dated April 27, 2021 (the “Agreement“) with Core One... Read more
Core One Labs to Explore Joint Venture with Lobe Sciences for the Clinical Development of Biosynthetic Psilocybin
April 28, 2021
Ryan Allway April 28th, 2021 Psychedelics VANCOUVER, British Columbia, April 28, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (“Core One”) is pleased to announce it has entered into a letter of intent, dated April 27, 2021, with Lobe Sciences Ltd. (“Lobe”) pursuant... Read more
MindMed To Commence Trading on Nasdaq
April 23, 2021
Ryan Allway April 23rd, 2021 Psychedelics NEW YORK, April 23, 2021 /PRNewswire/ — MindMed (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, announced today that the Company’s subordinate voting shares have been approved for listing on The Nasdaq Capital Market (“Nasdaq”). Trading is expected to begin on Tuesday, April 27, 2021,... Read more
NeonMind Announces New Specialty Clinics Division to Deliver Innovative Mental Health Services, Appoints New VP, Corporate Development
April 22, 2021
Vancouver, B.C. – April 22, 2021: NeonMind Biosciences Inc. (CSE: NEON)(OTC:NMDBF) (FFE: 6UF) (“NeonMind”), a psychedelic drug development company, is pleased to announce that it is establishing a medical services division for the delivery of evidence-backed innovative treatments for a variety of mental health needs. This will include psychedelic modalities and... Read more
TORONTO, April 22, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the successful completion of the research results and... Read more
Microdosing: The Next Revolution in Psychedelics
April 22, 2021
Ryan Allway April 22nd, 2021 App, Exclusive, Psychedelics, Top Story The psychedelics industry has experienced a renaissance over the past few years as researchers have opened a pandora’s box of potential. From major depression to generalized anxiety to post-traumatic stress disorder, emerging research suggests that psychedelic substances could have... Read more
